Please find enclosed herewith the Results for the Quarter and Half Year ended September 30, 2025.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Parnax Lab reported consolidated revenue from operations of Rs. 6,260 lakhs for Q2 FY26, up about 29% from Rs. 4,836 lakhs in Q2 FY25. For the half year (H1 FY26), consolidated revenue grew about 18% to Rs. 11,598 lakhs, driven mainly by subsidiary Naxpar Pharma which contributed Rs. 11,408 lakhs. Consolidated profit after tax for H1 FY26 was Rs. 690 lakhs, down about 6.8% from Rs. 740 lakhs in H1 FY25, with EPS falling to Rs. 6.01 from Rs. 6.44. Profit before tax margins compressed from around 10.3% in H1 FY25 to about 8.3% in H1 FY26 due to higher material and employee costs. The statutory auditor C.N. Patel & Co. issued clean (unmodified) limited review reports on both standalone and consolidated results.
Mixed picture for shareholders: top-line growth is healthy on the back of the pharma subsidiary, but profit margins are under pressure and bottom-line has actually shrunk year-on-year. This could weigh on the stock in the near term despite the revenue momentum.